Estimating the number of individuals who need to receive PrEP to meet England’s 2030 HIV transmission elimination goals

England has committed to eliminating HIV transmission by 20301. Although significant progress has been made in reducing new HIV diagnoses, existing evidence suggests increased investment in prevention efforts is required to meet the elimination target2,3. Pre-exposure prophylaxis (PrEP) is widely available through sexual health services in England: In 2024, 111,000 individuals accessed PrEP in sexual Read More >
When will the UK achieve HIV transmission elimination? Modelling the impact of current HIV prevention efforts on progress towards the 2030 elimination goal

In 2019, the previous UK government set the ambitious target of eliminating HIV transmission within the UK by 2030. While great progress has been made in HIV prevention and treatment in the UK, with England reaching the UNAIDS 95-95-95 target in 20231, past evidence suggested that the goal of ‘elimination’ by 2030 is unlikely to Read More >
An Implementation Tool For US Professionals: First Void Urine Self-Sampling for Primary HPV Cervical Cancer Screening

The national coverage of cervical cancer screening in the US is falling, with about 1 in 4 women not up to date with screening1. Under-screened women bear the greatest burden of disease. Evidence shows 60-64% of American women diagnosed with cervical cancer were unscreened, highlighting the need to explore alternative methods to improve access2-4. In Read More >
Mapping and comparing COPD Care Pathways across 10 countries to understand barriers to optimal care: clinicians’ perspectives
Care Pathway Mapping for Dravet Syndrome (DS) Patients in England
Analysing the COPD care pathway in Japan, Canada, England, and Germany: a global view
A Cost-Effectiveness Analysis of Fenfluramine for the Treatment of Seizures for Patients with Dravet Syndrome (DS) in the UK Setting
Determining the Relationship of Seizures, Seizure Free Days and Other Predictors of Health Related Quality of Life in Patients with Dravet Syndrome (DS) and Their Carers
Evaluating the benefits and costs of using an mRNA versus DNA HR-HPV assay in the National Cervical Screening Programme in the Netherlands
Modelling the impact of using a DNA compared to mRNA HPV assay as part of the cervical screening programmes in Sweden and Denmark